<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03936322</url>
  </required_header>
  <id_info>
    <org_study_id>18-008622</org_study_id>
    <nct_id>NCT03936322</nct_id>
  </id_info>
  <brief_title>Minimally Invasive Fetoscopic Regenerative Repair of Spina Bifida - A Pilot Study</brief_title>
  <official_title>Minimally Invasive Fetoscopic Regenerative Repair of Spina Bifida - A Pilot Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Mayo Clinic</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Mayo Clinic</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
    <is_unapproved_device>Yes</is_unapproved_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Researchers are studying a new minimally invasive technique (fetoscopic repair) for repair of&#xD;
      spina bifida (MMC) during the second trimester of pregnancy. Researchers are trying to&#xD;
      determine if this less invasive surgical approach will have less risk to the mother and at&#xD;
      the same time adequate closure of the fetal spina bifida defect.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">May 7, 2019</start_date>
  <completion_date type="Anticipated">December 2023</completion_date>
  <primary_completion_date type="Anticipated">June 2023</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Maternal adverse events</measure>
    <time_frame>5 years</time_frame>
    <description>Total number of maternal adverse events</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Neonatal adverse events</measure>
    <time_frame>5 years</time_frame>
    <description>Total number of neonatal adverse events</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">3</enrollment>
  <condition>Spina Bifida</condition>
  <condition>Myelomeningocele</condition>
  <condition>Neural Tube Defects</condition>
  <arm_group>
    <arm_group_label>Pregnant women diagnosed with fetal myelomeningocele</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Women subjects who are pregnant and diagnosed with myelomeningocele (MMC), also known as fetal spina bifida or neural tube defect, will undergo a minimally invasive fetoscopic repair of MMC.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Minimally invasive fetoscopic repair of MMC</intervention_name>
    <description>Uses a technique to open your belly (skin, muscles and abdomen) without opening the uterus, except for a small puncture, to repair the fetal spina bifida defect during the second trimester of pregnancy.</description>
    <arm_group_label>Pregnant women diagnosed with fetal myelomeningocele</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria&#xD;
&#xD;
          -  Pregnant women - maternal age 18 years or older&#xD;
&#xD;
          -  Gestational age at the time of the procedure between 19 0/7 weeks and 25 6/7 weeks&#xD;
&#xD;
          -  Singleton pregnancy.&#xD;
&#xD;
          -  MMC diagnosis with the upper boundary located between Thoracic 1 (T1) and Sacral&#xD;
&#xD;
             1 (S1).&#xD;
&#xD;
          -  Evidence of hindbrain herniation (confirmed on MRI to have an Arnold-Chiari type II&#xD;
             malformation).&#xD;
&#xD;
          -  Absence of chromosomal abnormalities and associated anomalies.&#xD;
&#xD;
          -  Normal karyotype and/or normal chromosomal microarray (CMA) by invasive testing&#xD;
             (amniocentesis or CVS). If there is a balanced translocation with normal CMA with no&#xD;
             other anomalies the candidate can be included.&#xD;
&#xD;
          -  Family has considered and declined the option of termination of the pregnancy at less&#xD;
             than 24 weeks.&#xD;
&#xD;
          -  Family meets psychosocial criteria (sufficient social support, ability to understand&#xD;
             requirements for this study).&#xD;
&#xD;
          -  Pregnant subject capable of consenting for their own participation in this study.&#xD;
&#xD;
          -  Willingness to undergo an open MMC repair, if necessary&#xD;
&#xD;
          -  Parental/guardian permission (informed consent) for follow up of child after birth.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Exclusion Criteria&#xD;
&#xD;
               -  Fetal anomaly unrelated to MMC.&#xD;
&#xD;
               -  Multiple gestation&#xD;
&#xD;
               -  Declined invasive testing for karyotype (amniocentesis or CVS)&#xD;
&#xD;
               -  Severe kyphosis (defined as curvature of the spina (vertebras) higher than 30o&#xD;
                  degree measured by ultrasonography or magnetic resonance imaging).&#xD;
&#xD;
               -  Increased risk for preterm labor including short cervical length (&lt;2.0 cm),&#xD;
                  history of incompetent cervix with or without cerclage, and previous preterm&#xD;
                  birth.&#xD;
&#xD;
               -  Placental abnormalities (previa, abruption, accreta) known at time of enrollment.&#xD;
&#xD;
               -  A body-mass index ≥40 at first prenatal visit.&#xD;
&#xD;
               -  Contraindications to surgery including previous hysterotomy (whether from a&#xD;
                  previous classical cesarean, uterine anomaly such as an arcuate or bicornuate&#xD;
                  uterus, major myomectomy resection, or previous fetal surgery) in active uterine&#xD;
                  segment.&#xD;
&#xD;
               -  Technical limitations precluding fetoscopic surgery, such as uterine fibroids,&#xD;
                  fetal membrane separation, uterine anomalies incompatible with fetoscopy.&#xD;
&#xD;
               -  Amniotic Fluid Index (AFI) &lt; 6 cm if deemed to be due to fetal anomaly, poor&#xD;
                  placental perfusion or function, or membrane rupture. Low amniotic fluid volume&#xD;
                  that responds to maternal hydration is not an exclusion.&#xD;
&#xD;
               -  Maternal-fetal Rh isoimmunization, Kell sensitization or neonatal alloimmune&#xD;
                  thrombocytopenia affecting the current pregnancy.&#xD;
&#xD;
               -  Maternal HIV, Hepatitis-B, Hepatitis-C status positive because of the increased&#xD;
                  risk of transmission to the fetus during maternal-fetal surgery. If the patients&#xD;
                  HIV or Hepatitis status is unknown, the patient must be tested and found to have&#xD;
                  negative results before enrollment.&#xD;
&#xD;
               -  Maternal medical condition that is a contraindication to surgery or anesthesia.&#xD;
&#xD;
               -  A score of ≥ 29 on the Beck Depression Inventory (BDI) at screening&#xD;
&#xD;
               -  Maternal hypersensitivity to collagen&#xD;
&#xD;
               -  Patient does not have a support person (i.e. Spouse, partner, mother) available&#xD;
                  to support the patient for the duration of the pregnancy.&#xD;
&#xD;
               -  Inability to comply with the travel and follow-up requirements of the trial.&#xD;
&#xD;
               -  Participation in another intervention study that influences maternal and fetal&#xD;
                  morbidity and mortality or participation in this trial in a previous pregnancy.&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Rodrigo Ruano, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Mayo Clinic</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Mayo Clinic in Rochester</name>
      <address>
        <city>Rochester</city>
        <state>Minnesota</state>
        <zip>55905</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>https://www.mayo.edu/research/clinical-trials</url>
    <description>Mayo Clinic Clinical Trials</description>
  </link>
  <verification_date>January 2021</verification_date>
  <study_first_submitted>May 1, 2019</study_first_submitted>
  <study_first_submitted_qc>May 1, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">May 3, 2019</study_first_posted>
  <last_update_submitted>January 25, 2021</last_update_submitted>
  <last_update_submitted_qc>January 25, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">January 27, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Mayo Clinic</investigator_affiliation>
    <investigator_full_name>Rodrigo Ruano M.D., Ph.D</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Spinal Dysraphism</mesh_term>
    <mesh_term>Meningomyelocele</mesh_term>
    <mesh_term>Spina Bifida Cystica</mesh_term>
    <mesh_term>Neural Tube Defects</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

